États-Unis · Places boursières & cours · Nasdaq

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

Publié par Nasdaq · États-Unis il y a 34 min

Résumé détaillé

Key PointsEli Lilly is one of the undisputed leaders in the weight loss market, and its progress in this area is helping it deliver excellent financial results.

Lire l'article complet sur Nasdaq Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (www.nasdaq.com)

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

Résumé détaillé

À lire aussi

Quantum Computing Is Being Pitched as the Fix for AI's Runaway Power Appetite

Sky (SKY) Token Declines 4% Amid Market Caution

401(k) Contribution Rates: How Does Your Savings Rate Stack Up by Age and Income?

A retired brigadier general weighs in on the diminishing veteran voices on Capitol Hill

The open AI-native stack on Kubernetes: From open models to distributed inference and agents

Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?

Résumé détaillé

Partager

À lire aussi

Quantum Computing Is Being Pitched as the Fix for AI's Runaway Power Appetite

Sky (SKY) Token Declines 4% Amid Market Caution

401(k) Contribution Rates: How Does Your Savings Rate Stack Up by Age and Income?

A retired brigadier general weighs in on the diminishing veteran voices on Capitol Hill

The open AI-native stack on Kubernetes: From open models to distributed inference and agents